Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and derivatives thereof

• US 5,602,171 A
• Filed: 06/07/1995
• Issued: 02/11/1997
• Est. Priority Date: 06/07/1995
• Status: Expired due to Fees

• Current Assignee: Sugen Incorporated (Pharmacia Corp.)
• Original Assignee: Sugen Incorporated (Pharmacia Corp.)
• Inventors: McMahon, Gerald, Tang, Peng C.
• Primary Examiner(s): Richter, Johann
• Assistant Examiner(s): LUTZ, LAURA REBEKAH
• Application Number:
  US08/481,955
• Time in Patent Office: 615 Days
• Field of Search: 514/455, 549/389
• US Class Current: 514/455
• CPC Class Codes: C07D 311/92 Naphthopyrans; Hydrogenated naphthopyrans

Abstract

The present invention relates to organic molecules capable of inhibiting protein tyrosine phosphatase activity. The invention further relates to the use of such molecules to modulate or regulate signal transduction by inhibiting protein tyrosine phosphatase activity. Finally, the invention relates to the use of such molecules to treat various disease states including diabetes mellitus.

Claims

1. A method of inhibiting protein tyrosine phosphatase activity which comprises administering to a mammal an effective amount of a compound having the formula (I):

##STR18## or a pharmaceutically acceptable salt thereof, wherein;

-- represents a single or double bond;

R1, R2, which are the same or different, are C1 to C4 substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group;

R4, R5, R6, which are the same or different, are H, OH, substituted or unsubstituted C1 to C4 alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted C1 to C6 alkyl, alkylaryl, arylalkoxy, ester, carboxylic acid, carboxamide, carbamate, or cyano;

R3 is a substituent identical to that of formula I providing a compound of formula II;

##STR19## or a pharmaceutically acceptable salt thereof;

or R₃ is a substituted or unsubstituted aryl group which links to formula I directly, or by amide, carbon or ketone groups.

4. The method of claim 1, 2 or 3 wherein said compound is ##STR24## or a pharmaceutically acceptable salt thereof.

5. The method of claim 1, 2 or 3 wherein said compound is ##STR25## or a pharmaceutically acceptable salt thereof.

6. The method of claim 1, 2 or 3 wherein said compound is ##STR26## or a pharmaceutically acceptable salt thereof.

7. The method of claim 1, 2 or 3 wherein said compound is ##STR27## or a pharmaceutically acceptable salt thereof.

2. A method of modulating signal transduction which comprises administering to a mammal an effective amount of a compound having the formula (I):

##STR20## or a pharmaceutically acceptable salt thereof, wherein;

-- represents a single or double bond;

R1, R2, which are the same or different, are C1 to C4 substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group;

R4, R5, R6, which are the same or different, are H, OH, substituted or unsubstituted C1 to C4 alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted C1 to C6 alkyl, alkylaryl, arylalkoxy, ester, carboxylic acid, carboxamide, carbamate, or cyano;

R3 is a substituent identical to that of formula I providing a compound of formula II;

##STR21## or a pharmaceutically acceptable salt thereof;

or R₃ is a substituted or unsubstituted aryl group which links to formula I directly or by amide, carbon or ketone groups;

said effective amount being sufficient to regulate protein tyrosine phosphatase activity.

8. The method of claim 2 wherein the signal transduction is upregulated so that the effect of ligand binding to a receptor is enhanced.

9. The method of claim 2 wherein the signal transduction is upregulated so that the effect of ligand binding to a receptor is mimicked.

10. The method of claim 8 or 9 wherein the receptor is a protein tyrosine kinase.

11. The method of claim 8 or 9 wherein the receptor is insulin receptor.

3. A method of treating Diabetes mellitus which comprises administering to a human an effective amount of a compound having the formula (I):

##STR22## or a pharmaceutically acceptable salt thereof, wherein;

-- represents a single or double bond;

R1, R2, which are the same or different, are C1 to C4 substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group;

R4, R5, R6, which are the same or different, are H, OH, substituted or unsubstituted C1 to C4 alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted C1 to C6 alkyl, alkylaryl, arylalkoxy, ester, carboxylic acid, carboxamide, carbamate, or cyano;

R3 is a substituent identical to that of formula I providing a compound of formula II;

##STR23## or a pharmaceutically acceptable salt thereof;

or R₃ is a substituted or unsubstituted aryl group which links to formula I directly or by amide, carbon or ketone groups;

said effective amount being sufficient to regulate protein tyrosine phosphatase activity.

12. A pharmaceutical composition which comprises an effective amount of a compound having the formula (I):

##STR28## or a pharmaceutically acceptable salt thereof, wherein;

-- represents a single or double bond;

R1, R2, which are the same or different, are C1 to C4 substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group;

R4, R5, R6, which are the same or different, are H, OH, substituted or unsubstituted C1 to C4 alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted C1 to C6 alkyl, alkylaryl, arylalkoxy, ester, carboxylic acid, carboxamide, carbamate, or cyano;

R3 is a substituent identical to that of formula I providing a compound of formula II;

##STR29## or a pharmaceutically acceptable salt thereof;

or R₃ is a substituted or unsubstituted aryl group which links to formula I directly or by amide, carbon or ketone groups; and

a pharmaceutically acceptable carrier.